Acurex Biosciences Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Later Stage VC
- Investors
-
3
Acurex Biosciences General Information
Description
Operator of a pharmaceutical company intended to halt major neurodegenerative diseases. The company specializes in supporting the impairment of mitophagy, by which cells dispose of dysfunctional mitochondria, which plays a significant role in the pathogenesis of PD and other diseases, enabling medical facilities to identify druggable targets responsible for defects in mitophagy.
Contact Information
Website
www.acurex.comCorporate Office
- 930 Brittan Avenue
- San Carlos, CA 94070
- United States
Corporate Office
- 930 Brittan Avenue
- San Carlos, CA 94070
- United States
Acurex Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 09-May-2025 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC | 01-Mar-2023 | Completed | Pre-Clinical Trials | |||
| 2. Grant | 27-Apr-2022 | $7M | Completed | Pre-Clinical Trials | ||
| 1. Grant | 30-Sep-2021 | $450K | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Acurex Biosciences Comparisons
Industry
Financing
Details
Acurex Biosciences Competitors (41)
One of Acurex Biosciences’s 41 competitors is Arvinas, a Formerly VC-backed company based in New Haven, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arvinas | Formerly VC-backed | New Haven, CT | ||||
| Ambagon Therapeutics | Venture Capital-Backed | Eindhoven, Netherlands | ||||
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| TME Pharma | Formerly VC-backed | Berlin, Germany | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE |
Acurex Biosciences Patents
Acurex Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022216386-A2 | T-type calcium channel antagonists and uses thereof | Inactive | 04-Mar-2021 | ||
| WO-2022216386-A3 | T-type calcium channel antagonists and uses thereof | Inactive | 04-Mar-2021 | ||
| WO-2022216386-A9 | T-type calcium channel antagonists and uses thereof | Inactive | 04-Mar-2021 | C07D471/04 |
Acurex Biosciences Signals
Acurex Biosciences Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Regents of the University of California | University | |||
| Innovations for Impact | Impact Investing | Minority | ||
| Michael J. Fox Foundation | Limited Partner |
Acurex Biosciences FAQs
-
When was Acurex Biosciences founded?
Acurex Biosciences was founded in 2019.
-
Where is Acurex Biosciences headquartered?
Acurex Biosciences is headquartered in San Carlos, CA.
-
What is the size of Acurex Biosciences?
Acurex Biosciences has 12 total employees.
-
What industry is Acurex Biosciences in?
Acurex Biosciences’s primary industry is Drug Discovery.
-
Is Acurex Biosciences a private or public company?
Acurex Biosciences is a Private company.
-
What is Acurex Biosciences’s current revenue?
The current revenue for Acurex Biosciences is .
-
Who are Acurex Biosciences’s investors?
Regents of the University of California, Innovations for Impact, and Michael J. Fox Foundation have invested in Acurex Biosciences.
-
Who are Acurex Biosciences’s competitors?
Arvinas, Ambagon Therapeutics, Agenus, TME Pharma, and Ayala Pharmaceuticals are some of the 41 competitors of Acurex Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process